aibioSanofi SA
Sanofi is a French drug and vaccine company whose largest product is the immunology antibody Dupixent.
- Ticker
- SAN
- Listing
- EURONEXT, France
- Next date
- October 30, 2026
- Chief executive
- Belén Garijo
Desk view · Opinion · Updated Oct 22, 2026
Sanofi grows on Dupixent as its new CEO prunes the pipeline
Sanofi's commercial business is growing fast on Dupixent and new launches, and it raised 2026 guidance. New leadership has cut several pipeline programs and taken large write-downs. The company now looks more dependent on Dupixent and on future deals.
Read the full desk viewaibio.space Investor Rank · Opinion
7/10 Positive view
Dupixent and launches drive fast growth and raised guidance, but three pipeline programs were dropped in 2026, leaving Sanofi more dependent on Dupixent and deals.
- Technology
- 2/2
- Odds
- 0/2
- Balance sheet
- 2/2
- Risk
- 1/2
- Momentum
- 2/2
Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. How the rank works.
- Technology
- Proven in immunology. Dupixent grew 37.6% to EUR 5.2 billion in Q2 2026, and launches grew 48.3% to EUR 1.3 billion.
- Odds
- Weaker in the pipeline. Amlitelimab, itepekimab and balinatunfib were dropped in 2026, leaving duvakitug and venglustat as the main near-term bets.
- Balance sheet
- Solid and profitable. Net debt was EUR 15.5 billion at June 30, 2026, with EUR 3.7 billion of first-half free cash flow.
- Main risk
- Dupixent dependence. One product made up about 44% of Q2 sales, and the 2030 plan builds on it.
- Watch next
- Q3 and venglustat. Results come October 30 and the FDA decision on venglustat by November 25, 2026.
Top news on Sanofi
Questions investors ask
What is aibio.space's Investor Rank for Sanofi SA?
7 out of 10, our positive view. Dupixent and launches drive fast growth and raised guidance, but three pipeline programs were dropped in 2026, leaving Sanofi more dependent on Dupixent and deals. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. Source
Who is the CEO of Sanofi?
Belén Garijo is Sanofi's chief executive officer. She commented on second-quarter 2026 results as CEO on July 30, 2026, describing her first months in the role. Source
When does Sanofi report Q3 2026 results?
Sanofi will publish third-quarter 2026 results on October 30, 2026. It released the aide-memoire for the quarter on October 6. Source
Why did Sanofi stop amlitelimab?
Sanofi said on July 24, 2026 that the totality of efficacy and safety data did not support further development in atopic dermatitis, and that the drug would not meaningfully improve on standard care. It took a EUR 952 million impairment related to amlitelimab in the second quarter. Source
What is Sanofi's 2026 guidance?
Sanofi raised its outlook on July 30, 2026. It expects 2026 sales to grow by around 10% at constant exchange rates, with business EPS growing slightly faster than sales. Source
How much are Dupixent sales?
Dupixent sales were EUR 5.2 billion in the second quarter of 2026, up 37.6% and above EUR 5 billion in a quarter for the first time. Sanofi expects about EUR 25 billion in 2030 at constant exchange rates. Source
Is Sanofi SA a smaller reporting company?
SEC records list Sanofi SA's filer category as: Large accelerated filer. Source
Where is Sanofi SA headquartered?
SEC records list its business address as 46 AVENUE DE LA GRANDE ARMEE, PARIS, France, 75017. Source
When does Sanofi SA's fiscal year end?
Sanofi SA's fiscal year ends on December 31, per SEC records. Source
What did Sanofi SA last file with the SEC?
Its most recent filing in our record is a 6-K filed 2026-10-01. All of its filings are on SEC EDGAR. Source
What was Sanofi SA called before?
SEC records list these former names: SANOFI-AVENTIS; SANOFI SYNTHELABO SA. Source
What industry is Sanofi SA in?
Its SEC industry code (SIC 2834) is Pharmaceutical Preparations. Source
Legal and investor matters
Note B.14 of the half-year report filed 2026-07-30 states that Sanofi and its affiliates are involved in litigation, arbitration and other legal proceedings. It describes product, patent, antitrust and other matters, including a nationwide antitrust class action filed by 340B covered entities (Mosaic Health). It covers that report only. Source
- Litigation
Delaware court dismisses Zantac cases pending against Sanofi; plaintiffs appeal
Sanofi's half-year report says the Delaware Superior Court granted summary judgment in the second quarter of 2026 and dismissed all Zantac cases pending against Sanofi there. Plaintiffs are appealing to the Delaware Supreme Court, with no decision expected before the fourth quarter of 2027. In the federal multi-district litigation, the Eleventh Circuit heard argument in late 2025, and a decision is now expected in the second half of 2026.
- Litigation
Dupixent lymphoma product cases consolidated into New Jersey federal MDL
Sanofi reports about 30 product liability cases in federal courts alleging that Dupixent causes or exacerbates T-cell lymphoma. In June 2026 those cases were consolidated into a multi-district litigation in New Jersey federal court. Eight more cases have been filed in New Jersey state court. Sanofi says it cannot reliably assess the outcome of the ongoing cases.
- Litigation
340B antitrust class action against Sanofi and three manufacturers proceeds
In July 2021, Mosaic Health and Central Virginia Health Services filed a nationwide antitrust class action in the Western District of New York against Sanofi and three other manufacturers, alleging a conspiracy to eliminate favorable 340B pricing on diabetes drugs. The Second Circuit remanded the case in August 2025. In July 2026 certain state law and unjust enrichment claims were dismissed, and fact discovery is set to close in November 2027.
- Litigation
Sanofi, Regeneron and Amgen settle European Praluent patent disputes
On March 6, 2026, Sanofi, Regeneron and Amgen entered into a settlement agreement resolving the European Praluent patent disputes; the terms are confidential. Amgen had filed an infringement action in the Unified Patent Court in June 2023. In November 2025 the UPC Court of Appeal reversed a July 2024 first-instance decision that had invalidated Amgen's patent, and Sanofi and Regeneron requested a rehearing. The half-year report says the cases are now closed.
- Litigation
Sanofi US pays $350 million to settle Hawaii attorney general Plavix action
The Hawaii attorney general sued Sanofi and Bristol Myers Squibb in March 2014, alleging that Plavix had a diminished effect in patients of certain genetic backgrounds and that the companies failed to make an earlier disclosure. A 2024 judgment totaled $916 million, with $458 million against Sanofi. In May 2025 the parties agreed to settle: Sanofi US paid $350 million and Bristol Myers Squibb paid $350 million. The appeal and the underlying case were dismissed, according to the 20-F filed February 17, 2026.
- Regulatory
Sanofi US discloses HHS-OIG subpoena on PBM agreements and DOJ Beyfortus demand
The 20-F filed February 17, 2026 states that in May 2025 Sanofi US received a subpoena from the HHS Office of Inspector General in Philadelphia about agreements with pharmacy benefit managers and group purchasing organizations, part of a joint investigation with the Department of Justice. In March 2025 it also received a DOJ civil investigative demand under the False Claims Act on Beyfortus. Sanofi says it is cooperating.
- Regulatory
State of Texas intervenes in Medicaid fraud qui tam suit against Sanofi US
Sanofi US was served in February 2024 with a qui tam complaint in Texas state court alleging violations of the Texas Medicaid Fraud Prevention Act. On February 13, 2026, the State of Texas filed a petition in intervention asserting a false certification theory of liability. Sanofi moved to disqualify one of the relator's law firms. Trial is scheduled for July 19, 2027, subject to the court's ruling on that motion.
- Regulatory
French authorities visit Sanofi headquarters in Parquet national financier preliminary investigation
On November 25, 2025, Sanofi's headquarters were visited by French authorities as part of an investigation by the Parquet national financier (PNF). Sanofi's 20-F filed February 17, 2026 says the investigation concerns a financing arrangement offered by Societe Generale in an acquisition transaction more than 10 years ago. It says the PNF is conducting a preliminary investigation related to allegations of money laundering, tax fraud and criminal conspiracy.
- Litigation
Texas attorney general sues Sanofi and Bristol Myers Squibb over Plavix warnings
On November 20, 2025, the Texas Attorney General filed a complaint in Harrison County, Texas, against Sanofi and Bristol Myers Squibb alleging a failure to warn that Plavix has diminished or no effect for some patients with a CYP2C19 genetic variation. It seeks civil penalties and recovery of Medicaid overpayments. The companies share the suit 50/50. A Travis County court abated their countersuit on April 28, 2026, and they sought mandamus on June 4, 2026.
- Regulatory
European Commission inspects Sanofi sites in flu vaccine antitrust probe
On September 29, 2025, European Commission representatives visited Sanofi premises in France and Germany in an investigation concerning seasonal flu vaccines. Sanofi says the Commission gave it a copy of a complaint by CSL Seqirus, which alleges that Sanofi disparaged its Fluad product in markets such as Germany where Sanofi would hold a dominant position. The complaint requests interim measures against Sanofi.
- Litigation
Paris appeals court orders Sanofi to pay about EUR 150 million to CNAM over Plavix
On September 24, 2025, the Paris Court of Appeal ordered Sanofi to pay the French national health insurer CNAM about EUR 150 million in damages. The court found harm from Sanofi's communication and promotional practices over five months from late 2009 to early 2010 that inhibited generic entry of Plavix. Sanofi appealed to the French Supreme Court in November 2025.
Pipeline
| Program | Indication | Stage |
|---|---|---|
| Duvakitug (TL1A antibody, with Teva) | Ulcerative colitis and Crohn's disease | Phase 3 (SUNSCAPE-1/-2, STARSCAPE-1/-2) Source |
| Venglustat | Type 3 Gaucher disease | FDA priority review, target action date Nov 25, 2026 Source |
| Cenrifki (tolebrutinib) | Non-relapsing secondary progressive multiple sclerosis | Approved in the EU, June 2026 Source |
| Frexalimab | Relapsing multiple sclerosis | Phase 3 data listed for 2027 Source |
| Riliprubart | Chronic inflammatory demyelinating polyneuropathy | Phase 3 VITALIZE continues; MOBILIZE stopped for futility Source |
Stock chart
SEC filings and registration
- SEC name
- Sanofi
- CIK
- 1121404
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- SNY (Nasdaq), SNYNF (OTC)
- State or country of incorporation
- I0
- Fiscal year ends
- December 31
- Filer category
- Large accelerated filer
- Business address
- 46 AVENUE DE LA GRANDE ARMEE, PARIS, France, 75017
- Phone
- 33153774400
- Shares outstanding
- 1,219,427,096 as of 2025-12-31 (20-F filed 2026-02-17)
- Former names
- SANOFI-AVENTIS; SANOFI SYNTHELABO SA
Recent filings
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction